|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 70.57 EGP | -1.27% |
|
-1.22% | +10.87% |
| 05-17 | GlaxoSmithKline Q1 consol net profit EGP 4.7 million | RE |
| 03-12 | GlaxoSmithKline S.A.E Reports Earnings Results for the Full Year Ended December 31, 2025 | CI |
| Market Cap | 5.89B 121M 105M 96.83M 90.17M 171M 11.47B 174M 1.16B 450M 5.62B 452M 443M 19.44B | P/E 2024 |
17.3x | P/E 2025 | 24.9x |
|---|---|---|---|---|---|
| Enterprise Value | 5.5B 112M 97.81M 90.29M 84.08M 160M 10.7B 162M 1.08B 419M 5.24B 422M 413M 18.13B | EV / Sales 2024 |
1.02x | EV / Sales 2025 | 1.32x |
| Free-Float |
2.91% | Yield 2024 * |
-
| Yield 2025 | 1.57% |
| 1 day | -1.27% | ||
| 1 week | -1.22% | ||
| Current month | +1.95% | ||
| 1 month | -4.93% | ||
| 3 months | +15.20% | ||
| 6 months | +13.66% | ||
| Current year | +10.87% |
| 1 week | 67 |  | 72.98 |
| 1 month | 66.75 | | 75.5 |
| Current year | 55.1 | | 79.99 |
| 1 year | 38.06 | | 81.5 |
| 3 years | 24.7 | | 81.5 |
| 5 years | 16.66 | | 81.5 |
| 10 years | 0 | | 81.5 |
| Manager | Title | Age | Since |
|---|---|---|---|
| Investor Relations Contact | - | - |
| Director | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | - | - | |
| Chairman | - | - | |
| Director/Board Member | - | - |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -1.27% | -1.22% | +84.45% | +122.20% | 122M | |
| +1.86% | +0.48% | +55.50% | +163.08% | 1,082B | |
| +3.57% | +3.29% | +68.60% | +61.03% | 633B | |
| +3.99% | +3.05% | +37.93% | +93.37% | 461B | |
| -0.26% | +1.37% | +31.00% | +23.97% | 338B | |
| -0.56% | +0.96% | +39.86% | +36.64% | 299B | |
| -0.08% | +1.30% | +30.37% | +44.02% | 291B | |
| -1.54% | +2.81% | -27.56% | -39.45% | 222B | |
| +3.55% | +4.41% | +25.45% | +66.28% | 202B | |
| +4.21% | +2.65% | +17.47% | +71.11% | 163B | |
| Average | +1.35% | +4.48% | +36.31% | +64.22% | 369.25B | |
| Weighted average by Cap. | +1.87% | +5.43% | +41.75% | +82.98% |
| 2024 | 2025 | |
|---|---|---|
| Net sales | 2.99B 61.16M 53.23M 49.14M 45.76M 86.83M 5.82B 88.15M 586M 228M 2.85B 230M 225M 9.87B | 3.73B 76.29M 66.4M 61.29M 57.08M 108M 7.26B 110M 731M 285M 3.56B 286M 280M 12.31B |
| Net income | 174M 3.56M 3.1M 2.86M 2.66M 5.05M 339M 5.13M 34.1M 13.28M 166M 13.35M 13.07M 574M | 213M 4.36M 3.79M 3.5M 3.26M 6.19M 415M 6.28M 41.79M 16.27M 203M 16.37M 16.01M 703M |
| Net Debt | 44.01M 900K 783K 723K 673K 1.28M 85.68M 1.3M 8.63M 3.36M 41.94M 3.38M 3.31M 145M | -398M -8.14M -7.08M -6.54M -6.09M -11.55M -775M -11.73M -77.99M -30.37M -379M -30.54M -29.89M -1.31B |
Employees
-
Sector
Pharmaceuticals
| Date | Price | Change | Volume |
|---|---|---|---|
| 05/07/26 | EGP 70.57 | -1.27% | 37,879 |
| 01/07/26 | EGP 71.48 | +3.26% | 28,729 |
| 30/06/26 | EGP 69.22 | +1.54% | 14,042 |
| 29/06/26 | EGP 68.17 | +1.17% | 31,113 |
- Stock Market
- Stocks
- BIOC Stock
Select your edition
All financial news and data tailored to specific country editions
